Figure 1: Precision Medicine: Treatment Tailored to an Individual’s Genetic Structure
Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care
Figure 3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 4: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Medicine Market
Figure 5: Global Precision Medicine Market (by Ecosystem), 2019 vs. 2030 ($Billion)
Figure 6: Global Precision Medicine Market (by Application Area), 2019 vs. 2030 ($Billion)
Figure 7: Global Precision Medicine Market (by Region) Snapshot
Figure 1.1: Global Precision Medicine Market Segmentation
Figure 1.2: Global Precision Medicine Market Methodology
Figure 3.1: Primary Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.1: Precision Medicine Approach
Figure 4.2: Evolution of Precision Medicine Technology
Figure 4.3: Precision Medicine: Enabling Technologies and Applications
Figure 4.4: Structured Big Data Reporting Benefits
Figure 4.5: Generalized Process for the Microarray
Figure 4.6: Global Precision Medicine Market: COVID-19 Impact
Figure 5.1: Impact Analysis
Figure 5.2: Percent of Patients Whose Tumor Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
Figure 6.1: Patent Analysis
Figure 6.2: Role of FDA in Advancing Precision Medicine
Figure 6.3: FDA Guidelines for CDx Approval
Figure 7.1: Share of Key Developments and Strategies, January 2012–July 2020
Figure 7.2: Synergistic Activities (January 2012- July 2020)
Figure 7.3: Product launches, Enhancements, and Upgradation by Companies (January 2012-July 2020)
Figure 7.4: Product Approvals by Companies (January 2012-July 2020)
Figure 7.5: Merger and Acquisitions Share by Companies (January 2012-July 2020)
Figure 7.6: Business Expansion Share by Companies (January 2012-July 2020)
Figure 7.7: Market Share Analysis for PM Applied Sciences Ecosystem, 2019
Figure 7.8: Market Share Analysis for PM Diagnostics Ecosystem, 2019
Figure 7.9: Market Share Analysis by PM Therapeutics Ecosystem, 2019
Figure 7.10: Market Share Analysis by PM Digital Health and IT Ecosystem, 2019
Figure 7.11: Share of Key Developments and Strategies, January 2014–February 2020
Figure 8.1: Precision Medicine: The Ecosystem
Figure 8.2: Global Precision Medicine Market (by Ecosystem)
Figure 8.3: Global Precision Medicine Market (by Ecosystem), 2019-2030
Figure 8.4: Global Precision Medicine Market (by Applied Sciences)
Figure 8.5: Global Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 8.6: Precision Medicine: Multi-omics Sciences
Figure 8.7: Global Precision Medicine Applied Sciences Market (by Type), 2019-2030
Figure 8.8: Precision Medicine: Genomics
Figure 8.9: Global Precision Medicine Genomics Market, 2019-2030
Figure 8.10: Global Precision Medicine Genomics Market (by Technology), 2019-2030
Figure 8.11: Global Precision Medicine PCR Market, 2019-2030
Figure 8.12: Global Precision Medicine PCR Market (by Product ), 2019-2030
Figure 8.13: Global Precision Medicine PCR Market (by End User), 2019-2030
Figure 8.14: Global Precision Medicine PCR Market (by Region), 2019-2030
Figure 8.15: Evolution of Next-Generation Sequencing
Figure 8.16: Global Precision Medicine NGS Market, 2019-2030
Figure 8.17: Global Precision Medicine NGS Market (by Product), 2019-2030
Figure 8.18: Global Precision Medicine NGS Market (by Technology), 2019-2030
Figure 8.19: Global Precision Medicine NGS Market (by End User), 2019-2030
Figure 8.20: Global Precision Medicine NGS Market (by Region), 2019-2030
Figure 8.21: Global Precision Medicine Genome Editing Market, 2019-2030
Figure 8.22: Global Precision Medicine Genome Editing Market (by Product), 2019-2030
Figure 8.23: Global Precision Medicine Genome Editing Market (by End User), 2019-2030
Figure 8.24: Global Precision Medicine Genome Editing Market (by Region), 2019-2030
Figure 8.25: Global Precision Medicine Other Technologies Market, 2019-2030
Figure 8.26: Global Precision Medicine Other Technologies Market (by Region), 2019-2030
Figure 8.27: Role of Biomarkers in Pharmacogenomics
Figure 8.28: Role of FDA In Pharmacogenomics
Figure 8.29: Global Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 8.30: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2019-2030
Figure 8.31: Global Precision Medicine Pharmacogenomics Market (by End User), 2019-2030
Figure 8.32: Global Precision Medicine Pharmacogenomics Market (by Region), 2019-2030
Figure 8.33: Global Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 8.34: Precision Medicine: Diagnostics
Figure 8.35: Global Precision Medicine Market (by Precision Diagnostics)
Figure 8.36: Global Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 8.37: Global Precision Medicine Diagnostics Market (by Type), 2019-2030
Figure 8.38: General Workflow of a Molecular Diagnostic Assay
Figure 8.39: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
Figure 8.40: Global Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 8.41: Global Precision Medicine Molecular Diagnostics Market (by Type), 2019-2030
Figure 8.42: Benefits and Risks Associated with NIPT
Figure 8.43: Global Precision Medicine NIPT Market, 2019-2030
Figure 8.44: Global Precision Medicine NIPT Market (by Platform), 2019-2030
Figure 8.45: Global Precision Medicine NIPT Market (by Region), 2019-2030
Figure 8.46: Drug and Companion Diagnostics Development Process
Figure 8.47: Benefits and Risks Associated with Companion Diagnostics
Figure 8.48: Global Precision Medicine Companion Diagnostics Market, 2019-2030
Figure 8.49: Global Precision Medicine Companion Diagnostics Market (by Technology), 2019-2030
Figure 8.50: Global Precision Medicine Companion Diagnostics Market (by Indication), 2019-2030
Figure 8.51: Global Precision Medicine Companion Diagnostics Market (by Region), 2019-2030
Figure 8.52: Clinical Applications of Liquid Biopsy
Figure 8.53: Global Precision Medicine Liquid Biopsy Market, 2019-2030
Figure 8.54: Global Precision Medicine Liquid Biopsy Market (by Indication), 2019-2030
Figure 8.55: Global Precision Medicine Liquid Biopsy Market (by Region), 2019-2030
Figure 8.56: Global Precision Medicine Other Molecular Diagnostics Market, 2020-2030
Figure 8.57: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2019-2030
Figure 8.58: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2019-2030
Figure 8.59: Global Precision Medicine Medical Imaging Market, 2019-2030
Figure 8.60: Global Precision Medicine Medical Imaging Market (by Type), 2019-2030
Figure 8.61: Global Precision Medicine Imaging Analytics Market, 2019-2030
Figure 8.62: Global Precision Medicine CADx Market, 2019-2030
Figure 8.63: Global Precision Medicine Medical Imaging Market (by Region), 2019-2030
Figure 8.64: Global Precision Medicine Digital Health and Information Technology Market, 2019-2030
Figure 8.65: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2019-2030
Figure 8.66: Global Precision Medicine CDSS Market, 2019-2030
Figure 8.67: Big Data Attributes
Figure 8.68: Global Precision Medicine Big Data Analytics Market, 2019-2030
Figure 8.69: Big Data Analytics: Key Benefits
Figure 8.70: Global Precision Medicine IT Infrastructure Market, 2019-2030
Figure 8.71: Global Precision Medicine IT Infrastructure Market (by Type), 2019-2030
Figure 8.72: Global Precision Medicine Genomics Informatics Market, 2019-2030
Figure 8.73: Global Precision Medicine Genomics Informatics Market (by Product Type), 2019-2030
Figure 8.74: Global Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 8.75: Global Precision Medicine Mobile Health Market, 2019-2030
Figure 8.76: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2019-2030
Figure 8.77: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2019-2030
Figure 8.78: Global Precision Medicine Therapeutics Market, 2019-2030
Figure 8.79: Global Precision Medicine Therapeutics Market (by Type), 2019-2030
Figure 8.80: Global Precision Medicine Clinical Trials Market, 2019-2030
Figure 8.81: Global Precision Medicine Clinical Trials Market (by Region), 2019-2030
Figure 8.82: Types of Cell Therapy
Figure 8.83: Global Precision Medicine Cell Therapy Market, 2019-2030
Figure 8.84: Global Precision Medicine Cell Therapy Market (by Region), 2019-2030
Figure 8.85: Global Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 8.86: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
Figure 8.87: Types of Gene Therapy
Figure 8.88: Types of Gene Therapy
Figure 8.89: Global Precision Medicine Gene Therapy Market, 2019-2030
Figure 8.90: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
Figure 9.1: Global Precision Medicine Applications Market, 2019-2030
Figure 9.2: Types of Cancer
Figure 9.3: Global Precision Medicine Oncology Market, 2019-2030
Figure 9.4: Global Precision Medicine Infectious Diseases Market, 2019-2030
Figure 9.5: Number of Deaths by Top 18 Infectious Diseases, 2018
Figure 9.6: Global Precision Medicine Neurology Market, 2019-2030
Figure 9.7: Global Precision Medicine Cardiovascular Market, 2019-2030
Figure 9.8: Global Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
Figure 9.9: Global Precision Medicine Gastroenterology Market, 2019-2030
Figure 9.10: Global Precision Medicine Other Applications Market, 2019-2030
Figure 10.1: Global Precision Medicine Market (by Region), 2019 and 2030
Figure 10.2: Global Precision Medicine Market (by Region), 2019-2030
Figure 10.3: North America Precision Medicine Market, 2019-2030
Figure 10.4: North America: Market Dynamics
Figure 10.5: North America Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.6: North America Precision Medicine Market (by Country), 2019-2030
Figure 10.7: U.S. Precision Medicine Market, 2019-2030
Figure 10.9: Europe Precision Medicine Market, 2019-2030
Figure 10.10: Europe: Market Dynamics
Figure 10.11: Europe Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.12: Europe Precision Medicine Market (by Country), 2019-2030
Figure 10.13: Germany Precision Medicine Market, 2019-2030
Figure 10.14: France Precision Medicine Market, 2019-2030
Figure 10.15: Italy Precision Medicine Market, 2019-2030
Figure 10.16: The U.K. Precision Medicine Market, 2019-2030
Figure 10.17: Spain Precision Medicine Market, 2019-2030
Figure 10.18: Rest-of-Europe Precision Medicine Market, 2019-2030
Figure 10.19: Asia-Pacific Precision Medicine Market, 2019-2030
Figure 10.20: APAC: Market Dynamics
Figure 10.21: Asia-Pacific Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.22: Asia-Pacific Precision Medicine Market (by Country), 2019-2030
Figure 10.23: China Precision Medicine Market, 2019-2030
Figure 10.24: Japan Precision Medicine Market, 2019-2030
Figure 10.25: Australia Precision Medicine Market, 2019-2030
Figure 10.26: India Precision Medicine Market, 2019-2030
Figure 10.27: Rest-of-Asia-Pacific Precision Medicine Market, 2019-2030
Figure 10.28: Latin America Precision Medicine Market, 2019-2030
Figure 10.29: APAC: Market Dynamics
Figure 10.30: Latin America Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.31: Latin America Precision Medicine Market (by Country), 2019-2030
Figure 10.32: Brazil Precision Medicine Market, 2019-2030
Figure 10.33: Mexico Precision Medicine Market, 2019-2030
Figure 10.34: Rest-of-Latin America Precision Medicine Market, 2019-2030
Figure 10.35: Rest-of-the-World Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.36: Rest-of-the-World Precision Medicine Market, 2019-2030
Figure 11.1: Total Number of Companies Profiled
Figure 11.2: Abbott Laboratories: Product Portfolio
Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 11.7: Abbott Laboratories: SWOT Analysis
Figure 11.8: Almac Group Ltd.: SWOT Analysis
Figure 11.9: Abbott Laboratories: Product Portfolio
Figure 11.10: Amgen Inc.: Overall Financials, 2017-2019
Figure 11.11: Amgen Inc.: Revenue (by Region), 2018-2019
Figure 11.12: Amgen Inc. R&D Expenditure, 2017-2019
Figure 11.13: Amgen Inc.: SWOT Analysis
Figure 11.14: ANGLE plc: Overall Financials, 2017-2019
Figure 11.15: ANGLE plc: Revenue (by Region), 2018-2019
Figure 11.16: ANGLE plc R&D Expenditure, 2017-2019
Figure 11.17: ANGLE plc: SWOT Analysis
Figure 11.18: Astellas Pharma Inc.: Product Portfolio
Figure 11.19: Astellas Pharma Inc.: Overall Financials, 2017-2019
Figure 11.20: Astellas Pharma Inc. R&D Expenditure, 2017-2019
Figure 11.21: Astellas Pharma Inc.: SWOT Analysis
Figure 11.22: Astra Zeneca: Product Portfolio
Figure 11.23: Astra Zeneca: Overall Financials, 2017-2019
Figure 11.24: Astra Zeneca: Revenue (by Business Segment), 2017-2019
Figure 11.25: Astra Zeneca: Revenue (by Region), 2017-2019
Figure 11.26: Astra Zeneca: SWOT Analysis
Figure 11.27: ASURAGEN INC.: SWOT Analysis
Figure 11.28: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 11.29: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 11.30: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 11.31: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
Figure 11.32: Bio-Rad Laboratories, Inc: SWOT Analysis
Figure 11.33: bioMérieux S.A.: Product Portfolio
Figure 11.34: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 11.35: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 11.36: bioMérieux S.A.: Revenue (by Region), 2018-2019
Figure 11.37: bioMérieux S.A.: SWOT Analysis
Figure 11.38: Bristol-Myers Squibb Company: Product Portfolio
Figure 11.39: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 11.40: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
Figure 11.41: Bristol-Myers Squibb Company.: SWOT Analysis
Figure 11.42: Cardiff Oncology.: Product Portfolio
Figure 11.43: Cardiff Oncology: Overall Financials, 2018-2019
Figure 11.44: Cardiff Oncology: R&D Expenditure, 2018-2019
Figure 11.45: Cardiff Oncology: SWOT Analysis
Figure 11.46: CETICS Healthcare Technologies GmbH: SWOT Analysis
Figure 11.47: Danaher Corporation: Overall Financials, 2017-2019
Figure 11.48: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 11.49: Danaher Corporation: SWOT Analysis
Figure 11.50: Eli Lilly and Company Limited: Product Portfolio
Figure 11.51: Eli Lilly and Company Limited: Overall Financials, 2017-2019
Figure 11.52: Eli Lilly and Company Limited: Revenue (by Region), 2018-2019
Figure 11.53: Eli Lilly and Company Limited: SWOT Analysis
Figure 11.54: Epic Sciences, Inc.: Product Portfolio
Figure 11.55: Epic Sciences, Inc.: SWOT Analysis
Figure 11.56: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 11.57: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 11.58: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 11.59: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 11.60: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 11.61: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 11.62: GE Healthcare: Product Portfolio
Figure 11.63: General Electric Company: Overall Financials, 2017-2019
Figure 11.64: General Electric Company: Revenue Split for Healthcare, 2017-2019
Figure 11.65: General Electric: Healthcare Revenue (by Region), 2017-2019
Figure 11.66: General Electric Company: R&D Expenditure, 2017-2019
Figure 11.67: General Electric Company: SWOT Analysis
Figure 11.68: Gilead Sciences, Inc.: Product Portfolio
Figure 11.69: Gilead Science, Inc.: SWOT Analysis
Figure 11.70: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 11.71: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 11.72: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 11.73: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 11.74: GlaxoSmithKline plc: SWOT Analysis
Figure 11.75: Illumina, Inc.: Product Portfolio
Figure 11.76: Illumina, Inc.: Overall Financials, 2017-2019
Figure 11.77: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 11.78: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 11.79: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 11.80: Illumina, Inc.: SWOT Analysis
Figure 11.81: Intomics A/S: SWOT Analysis
Figure 11.82: Illumina, Inc.: Product Portfolio
Figure 11.83: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
Figure 11.84: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
Figure 11.85: Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 11.86: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 11.87: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 11.88: Konica Minolta, Inc.: SWOT Analysis
Figure 11.89: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 11.90: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 11.91: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 11.92: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 11.93: MDx Health, Inc.: Overall Financials, 2017--2019
Figure 11.94: MDx Health, Inc.: SWOT Analysis
Figure 11.95: Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure 11.96: Merck KGaA: Product Portfolio
Figure 11.97: Merck KGaA: Overall Financials, 2017-2019
Figure 11.98: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 11.99: Merck KGaA: Revenue (by Region), 2017-2019
Figure 11.100: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
Figure 11.101: Merck KGaA: R&D Expenditure, 2017-2019
Figure 11.102: Merck KGaA: SWOT Analysis
Figure 11.103: Myriad Genetics, Inc.: Product Portfolio
Figure 11.104: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 11.105: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 11.106: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 11.107: Myriad Genetics, Inc.: SWOT Analysis
Figure 11.108: Novartis AG: Overall Product Portfolio
Figure 11.109: Novartis AG: Overall Financials, 2017-2019
Figure 11.110: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 11.111: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 11.112: Novartis AG: R& D Expense, 2017-2019
Figure 11.113: Novartis AG: SWOT Analysis
Figure 11.114: Oracle Corporation: Overall Financials, 2017-2019
Figure 11.115: Oracle Corporation: Revenue (by Region), 2017-2019
Figure 11.116: Oracle Corporation R&D Expenditure, 2017-2019
Figure 11.118: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 11.119: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 11.120: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 11.121: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 11.122: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 11.123: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 11.124: Partek, Inc.: SWOT Analysis
Figure 11.125: Pfizer Inc.: Overall Product Portfolio
Figure 11.126: Pfizer Inc.: Overall Financials, 2017-2019
Figure 11.127: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 11.128: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 11.129: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 11.130: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 11.131: Pfizer Inc.: SWOT Analysis
Figure 11.132: QIAGEN N.V.: Portfolio
Figure 11.133: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 11.134: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 11.135: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 11.136: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 11.137: QIAGEN N.V.: SWOT Analysis
Figure 11.138: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 11.139: Quest Diagnostics Incorporated: SWOT Analysis
Figure 11.140: Randox Laboratories Ltd.: SWOT Analysis
Figure 11.141: Sanofi SA: Product Portfolio
Figure 11.142: Sanofi SA: Overall Financials, 2017-2019
Figure 11.143: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 11.144: Sanofi SA: Revenue (by Region), 2017-2019
Figure 11.145: Sanofi SA: R&D Expenditure, 2017-2019
Figure 11.146: Sanofi SA: SWOT Analysis
Figure 11.147: Sysmex Corporation: Overall Financials, 2017-2019
Figure 11.148: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
Figure 11.149: Sysmex Corporation R&D Expenditure, 2017-2019
Figure 11.150: Sysmex Corporation: SWOT Analysis
Figure 11.151: Teva Pharmaceuticals Industries Ltd.: Product Portfolio
Figure 11.152: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
Figure 11.153: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
Figure 11.154: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
Figure 11.155: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
Figure 11.156: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 11.157: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 11.158: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 11.159: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 11.160: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 11.161: Thermo Fisher Scientific Inc.: SWOT Analysis